Bifrost Biosystems

Bifrost Biosystems, founded in 2021 and based in San Diego, is pioneering an optical pooled screening platform that bridges high-content cellular imaging with next-generation sequencing in a single, integrated system. This technology allows for the simultaneous analysis of tens of millions of individual cells, connecting rich phenotypic data to specific CRISPR-based genetic perturbations to de-risk and accelerate early-stage drug discovery. The company operates at the intersection of diagnostics and AI/machine learning, providing a powerful tool for mapping disease pathways, identifying novel drug targets, and understanding complex biological systems. Bifrost's mission is to democratize access to this technology, enabling better and faster decision-making in therapeutic development.

Integrated optical pooled screening platform combining high-speed microscopy, in situ sequencing, and AI/ML software to link single-cell phenotypes to genotypes for CRISPR-based functional genomics.

Bifrost competes with providers of arrayed screening services/instruments (e.g., Revvity, Sartorius) and standard, non-imaging pooled CRISPR screening services. Its unique value proposition is merging high-content imaging with pooled screening scale, a niche with few direct competitors but where several academic labs and potentially other startups are active.